IOVA insider trading — Iovance Biotherapeutics, Inc.
No open-market insider purchases or sales were filed for Iovance Biotherapeutics, Inc. (IOVA) in the last 90 days. Other insider transactions — such as stock awards, option exercises or tax withholding — are listed below.
Updated Oct 16, 2026.
Recent IOVA insider transactions
Every Form 4 filed by Iovance Biotherapeutics, Inc. officers, directors and 10% owners in the last 90 days, newest first. P = open-market purchase, S = open-market sale; other codes are awards, option exercises, tax withholding or gifts.
| Trade date | Insider | Role | Type | Ownership | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|---|
| Sep 8, 2026 | Vogt Frederick G | Interim CEO & General Counsel | M · Option exercise | Direct | 15,626 | — | — | Form 4 |
| Sep 8, 2026 | Vogt Frederick G | Interim CEO & General Counsel | F · Tax withholding | Direct | 6,638 | $8.70 | $58K | Form 4 |
| Sep 8, 2026 | Puri Raj K. | Chief Regulatory Officer | M · Option exercise | Direct | 9,766 | — | — | Form 4 |
| Sep 8, 2026 | Puri Raj K. | Chief Regulatory Officer | F · Tax withholding | Direct | 4,478 | $8.70 | $39K | Form 4 |
| Sep 8, 2026 | Bilinsky Igor | Chief Operating Officer | M · Option exercise | Direct | 7,813 | — | — | Form 4 |
| Sep 8, 2026 | Bilinsky Igor | Chief Operating Officer | F · Tax withholding | Direct | 3,976 | $8.70 | $35K | Form 4 |
| Sep 1, 2026 | Puri Raj K. | Chief Regulatory Officer | M · Option exercise | Direct | 5,470 | — | — | Form 4 |
| Sep 1, 2026 | Puri Raj K. | Chief Regulatory Officer | F · Tax withholding | Direct | 2,508 | $8.28 | $21K | Form 4 |
| Sep 1, 2026 | Vogt Frederick G | Interim CEO & General Counsel | M · Option exercise | Direct | 41,669 | — | — | Form 4 |
| Sep 1, 2026 | Vogt Frederick G | Interim CEO & General Counsel | F · Tax withholding | Direct | 17,702 | $8.28 | $147K | Form 4 |
| Sep 1, 2026 | Bilinsky Igor | Chief Operating Officer | M · Option exercise | Direct | 8,789 | — | — | Form 4 |
| Sep 1, 2026 | Bilinsky Igor | Chief Operating Officer | F · Tax withholding | Direct | 4,472 | $8.28 | $37K | Form 4 |
| Aug 10, 2026 | Kirby Daniel Gordon | Chief Commercial Officer | M · Option exercise | Direct | 10,001 | — | — | Form 4 |
| Aug 10, 2026 | Kirby Daniel Gordon | Chief Commercial Officer | F · Tax withholding | Direct | 2,436 | $6.40 | $16K | Form 4 |
| Aug 6, 2026 | Roche Corleen M. | Chief Financial Officer | M · Option exercise | Direct | 49,995 | — | — | Form 4 |
| Aug 6, 2026 | Roche Corleen M. | Chief Financial Officer | F · Tax withholding | Direct | 21,238 | $6.21 | $132K | Form 4 |
IOVA insider trading FAQ
Are insiders buying IOVA stock?
Not on the open market. In the last 90 days, Iovance Biotherapeutics, Inc. insiders made no open-market purchases, and no open-market sales. Purchases with the insider's own money are generally seen as a stronger signal than sales, which happen for many reasons (taxes, diversification, planned 10b5-1 sales).
Who are the insiders trading IOVA?
No insider bought or sold on the open market in the last 90 days.
Where does IOVA insider trading data come from?
Every transaction comes from SEC Form 4 filings on EDGAR. Company officers, directors and 10% owners must file a Form 4 within two business days of buying or selling. InsiderBolt reads these filings directly from the SEC.
More stocks with insider activity
Insider trading data is for informational purposes only and is not investment advice. Filings can be amended; always confirm details on SEC EDGAR.